Let's call it the Permutation Curve. Simply put, this curve is the exponential explosion of new possibilities from the ...

The MIT model predicts molecular binding affinity at newfound speed and accuracy, offering a powerful tool for commercial drug discovery.

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical ...

In an effort to save costs and make its financial resources last longer, Recursion Pharmaceuticals (NASDAQ: RXRX) is slimming ...

Recursion Pharmaceuticals continues to have a pipeline of drugs that might provide further validation for the company's ...

Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to ...

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.

Recursion Pharmaceuticals plans to slash one-fifth of its workforce as it looks to streamline its operations. The clinical-stage biopharmaceutical company said Tuesday it will reduce its workforce by ...

Based on its latest expense profile and business plan, after cutting its staff, Recursion said it now expects its projected cash runway to extend into the fourth quarter of 2027. Recursion will pay ...

We recently published a list of 15 Stocks That Stole The Show Last Week. In this article, we are going to take a look at ...

Recursion Pharmaceuticals said on Tuesday it will lay off around 20% of its workforce and focus on developing drugs for rare diseases and cancers to reduce cash burn during a prolonged biotech ...

We are at a turning point where artificial intelligence systems are beginning to operate beyond human control. These systems ...